Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-3 long-term extension of inclisiran versus evolocumab
NL-OMON55880Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of inclisiran and evolocumab in atherosclerotic disease and hypercholesterolemia (2 arms), sponsored by Novartis. Primary endpoints: Primary LDL-C change at Day 210 and Lipid and biomarker panel. Started Aug 2017; status: completed.
02
Drugs
inclisiranevolocumab
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on NL-OMON55880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55880.